Deal-Making
thumbnail
Deal MakingAstraZeneca scoops up rare disease firm Amolyt in $1bn dealAstraZeneca scoops up rare disease firm Amolyt in $1bn deal
AstraZeneca is set to acquire clinical-stage biotechnology firm Amolyt Pharma, which is focused on developing treatments for rare endocrine diseases.